Dacomitinib
Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
Sold as Vizimpro
- Drug class
- Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
- Availability
- See label
- Markets covered
- 2
- Products on record
- 7
Overview
Dacomitinib is an active pharmaceutical ingredient in the Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors group (L01EB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | September 5, 2025 |
| EU European Union | EMA | 1 | December 17, 2024 |
GBUnited Kingdom· MHRA
6 products
Uses
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
How to take
EUEuropean Union· EMA
1 product
Uses
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. 3
How to take
Drug interactions
Known interactions involving Dacomitinib. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000571678 · revised September 5, 2025
- [2]European Medicines Agency · EMEA/H/C/004779 · revised December 17, 2024
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.